Apolipoprotein L1: from obscurity to consistency to controversy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 25549121.
- Also identified by DOI 10.1038/ki.2014.319.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Apolipoprotein L1 (APOL1) is associated with increased incidence of chronic kidney disease (CKD) and end-stage renal disease, and with faster progression of CKD, in African Americans. APOL1 is expressed in intra- and extrarenal vascular tissue, making it a candidate to explain the increased incidence of cardiovascular disease in CKD. This Commentary discusses the disparate results from three studies showing that APOL1 renal risk genotypes are either harmful, neutral, or protective in the context of cardiovascular disease.
Medical subject headings
- Apolipoproteins
- Atherosclerosis
- Cardiovascular Diseases
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Kidney Diseases
- Lipoproteins, HDL
- Renal Insufficiency, Chronic